Related Experiment Video
Updated: Apr 13, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Small-molecule MDM2-p53 inhibitors: recent advances
Bian Zhang1, Bernard T Golding, Ian R Hardcastle
1Newcastle Cancer Centre, School of Chemistry, Bedson Building, Newcastle University, NE1 7RU, UK.
Abstract:
Potent and selective small-molecule inhibitors of the p53-MDM2 interaction intended for the treatment of p53 wild-type tumors have been designed and optimized in a number of chemical series. This review details recent disclosures of compounds in advanced optimization and features key series that have given rise to clinical trial candidates. The structure-activity relationships for inhibitor classes are discussed with reference to x-ray structures, and common structural features are identified.
Related Concept Videos
Abnormal Proliferation
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Inhibition of Cdk Activity
Inhibition of CDK Activity
Negative Regulator Molecules

